ibudilast and Depression

ibudilast has been researched along with Depression in 4 studies

Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.

Research

Studies (4)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF).

To evaluate the activity of ibudilast (100 mg/day) versus placebo at 96 weeks as measured by quantitative magnetic resonance imaging (MRI) analysis for whole brain atrophy using brain parenchymal fraction (BPF), calculated as the ratio of brain parenchymal tissue volume to the total volume contained within the brain surface contour. (NCT01982942)
Timeframe: 96 weeks

Magnetization Transfer Ratio (MTR) Imaging in Normal-appearing Brain Tissue

A magnetization transfer MRI as a marker of brain myelin content including the cerebral cortex could be useful. MT imaging provides access to the restricted protons, which are located in biologically interesting tissue regions.Cortical and normal appearing grey matter MTR correlates strongly with measures of disability such as the multiple sclerosis functional composite score and can show treatment effects. (NCT01982942)
Timeframe: 96 weeks

New T1 Lesions Since Baseline

New T1 lesions since baseline as measured by least square mean (90% confidence interval). (NCT01982942)
Timeframe: 96 weeks

Percentage of Participants With Adverse Events.

Safety Measures: percentage of participants who experienced treatment-emergent adverse events, clinically significant abnormal laboratory and electrocardiogram results. (NCT01982942)
Timeframe: 96 weeks

Retinal Nerve Fiber Layer as Measured by Optical Coherence Tomography (OCT).

Mean retinal nerve fiber layer thickness from baseline measured by Optical coherence tomography (OCT), a non-invasive imaging technique used to obtain high-resolution cross-sectional images of the retina. Increase in thickness is considered improvement. (NCT01982942)
Timeframe: 96 weeks

Diffusion Tensor Imaging (DTI) in Descending Pyramidal White Matter Tracts

Diffusion tensor imaging estimates the three-dimensional diffusion of water in brain tissue and has been explored as an outcome in MS. (NCT01982942)
Timeframe: 48 weeks

Any Drinking

Medication effects on number of days where any drinking was reported. . Values indicate estimated probability of a drinking day across time for each group. (NCT03489850)
Timeframe: 14 days

Heavy Drinking

Medication effects on number of heavy drinking days. Heavy drinking is defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as ≥5 drinks/day for men and ≥4 drinks/day for women. Values indicate estimated probability of a heavy drinking day across time for each group. (NCT03489850)
Timeframe: 14 days

Negative Affect

"Negative affect as measured by self-reported ratings of Downhearted, Discouraged, Uneasy, and Anxious. Each item was rated on a scale from 0 (not at all) to 4 (extremely). The 4 items were summed for the total negative affect score for each day, ranging from 0 - 16. Higher scores indicate more negative mood." (NCT03489850)
Timeframe: Assessed through daily prompts throughout the 2-week study period.

Ventral Striatum Activation

Medication effect on alcohol cue-induced ventral striatal activation. Participants completed an fMRI alcohol cue-reactivity paradigm where they viewed pictures of alcoholic beverages, non-alcoholic beverages, blurred images, and a plus sign. The mean percent signal change between the ALC and BEV blocks was extracted from an a priori defined region of interest: bilateral ventral striatum (VS), 6 mm-radius sphere centered at ±12 6 9 in MNI space. (NCT03489850)
Timeframe: Day 8

Trials

2 trials available for ibudilast and Depression

Other Studies

2 other studies available for ibudilast and Depression